Matthew Fitzgibbon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew Fitzgibbon has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Ashley V. DiMarco
Department of Translational Oncology, Genentech, Inc., South San Francisco, California
20 shared publications - Brock J. McKinney
Center for Immunity and Immunotherapies, Seattle Children’s Research Institute 1 , Seattle, WA
20 shared publications - Feinan Wu
Genomics and Bioinformatics Shared Resources, Fred Hutchinson Cancer Center, Seattle, WA, USA
20 shared publications - James V. Alvarez
Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
20 shared publications - Jessica N. Becerra
Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
20 shared publications - Nina Marie G. Garcia
Translational Research Program, Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, Washington
20 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary datatable 2 with analysis by clinical characteristics
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary datatable 2 with analysis by clinical characteristics
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S4. Variant allele frequency in KS tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S4. Variant allele frequency in KS tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S3. Recurrent gains and losses.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S3. Recurrent gains and losses.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary data table 1 with mutation report
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Supplementary data table 1 with mutation report
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S1. Analysis of KS exome sequencing.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S1. Analysis of KS exome sequencing.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S2. Mutations in KS exome tumors.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S2. Mutations in KS exome tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S5. Mutational signatures in KS lesions.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Figure S5. Mutational signatures in KS lesions.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Table S1. Clonal architecture identified with PyClone
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Table S1. Clonal architecture identified with PyClone
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Kaposi sarcoma is a frequently aggressive malignancy caused by Kaposi sarcoma herpesvirus. People with immunodeficiencies, including human immunodeficiency virus (HIV), are at increased risk for developing Kaposi sarcoma, but our understanding of the contributions of the cellular genome to Kaposi sarcoma pathogenesis remains limited. To determine if there are cellular genetic alterations in Kaposi sarcoma that might provide biological or therapeutic insights, we performed whole-exome sequencing on 78 Kaposi sarcoma tumors and matched normal control skin from 59 adults with Kaposi sarcoma (46 with HIV-associated Kaposi sarcoma and 13 with HIV-negative Kaposi sarcoma) receiving treatment at the Uganda Cancer Institute in Kampala, Uganda. We found a very low mutational burden in all but one specimen (median = 11 mutations), which is the lowest number of mutations among all 33 tumor types in The Cancer Genome Atlas. No recurrent mutations were seen, and the most commonly affected oncogenic pathway was RTK/RAS. Mutational signatures included defective DNA mismatch repair and smoking. There was no evidence suggesting that multiple tumors from the same patient originated from the same original clone. The number of genome copy alterations per genome was higher in tumors from those without HIV infection and in tumors from participants with advanced stage disease, suggesting that lesions that take longer to develop may accumulate more alterations, although the number of alterations remains low compared with other cancers.Implications:Our findings indicate that the pathogenesis of Kaposi sarcoma differs from other malignancies and that the primary driver of carcinogenesis is Kaposi sarcoma–associated herpesvirus infection and expression of viral oncogenes, rather than clonal oncogenic transformation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Exome Sequencing Reveals a Sparse Genomic Landscape in Kaposi Sarcoma
Kaposi sarcoma is a frequently aggressive malignancy caused by Kaposi sarcoma herpesvirus. People with immunodeficiencies, including human immunodeficiency virus (HIV), are at increased risk for developing Kaposi sarcoma, but our understanding of the contributions of the cellular genome to Kaposi sarcoma pathogenesis remains limited. To determine if there are cellular genetic alterations in Kaposi sarcoma that might provide biological or therapeutic insights, we performed whole-exome sequencing on 78 Kaposi sarcoma tumors and matched normal control skin from 59 adults with Kaposi sarcoma (46 with HIV-associated Kaposi sarcoma and 13 with HIV-negative Kaposi sarcoma) receiving treatment at the Uganda Cancer Institute in Kampala, Uganda. We found a very low mutational burden in all but one specimen (median = 11 mutations), which is the lowest number of mutations among all 33 tumor types in The Cancer Genome Atlas. No recurrent mutations were seen, and the most commonly affected oncogenic pathway was RTK/RAS. Mutational signatures included defective DNA mismatch repair and smoking. There was no evidence suggesting that multiple tumors from the same patient originated from the same original clone. The number of genome copy alterations per genome was higher in tumors from those without HIV infection and in tumors from participants with advanced stage disease, suggesting that lesions that take longer to develop may accumulate more alterations, although the number of alterations remains low compared with other cancers.Implications:Our findings indicate that the pathogenesis of Kaposi sarcoma differs from other malignancies and that the primary driver of carcinogenesis is Kaposi sarcoma–associated herpesvirus infection and expression of viral oncogenes, rather than clonal oncogenic transformation.
- Open Access
- 21 May 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
EGFR inhibitor-induced APOBEC activity is attenuated following single knockouts of A3A and A3B.
- 21 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer
EGFR inhibitor-induced APOBEC activity is attenuated following single knockouts of A3A and A3B.